Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Epilepsy (Jan 2021)

Trends That Matter for MCO's Role in COVID Vaccine Rollout

Radar On Market Access: Centene, UnitedHealth Ring in New Year With M&A

Radar On Market Access: FDA Approves First Oral Treatment for HAE Attack Prevention

MMIT Reality Check on Non-Small Cell Lung Cancer ALK+ or ROS1+ (Jan 2021)

Perspectives on New-to-Market Oral Drugs

Radar On Market Access: Supreme Court's ACA Ruling May Upend Biosimilars Market

Radar On Market Access: Despite New Approvals, Plans Still Favor Generics for Epilepsy

MMIT Reality Check on Metastatic Prostate Cancer (Dec 2020)

Trends That Matter for COVID Vaccine Distribution

Radar On Market Access: Surprise Medical Billing Comes to An End, Insurers Oppose Arbitration Mechanism

Radar On Market Access: PBMs Continue Integration, Face More Regulatory Challenges in 2020

MMIT Reality Check on Migraine Prevention (Dec 2020)

Perspectives on Amazon Pharmacy

Radar On Market Access: MCO Messaging Plays Key Role in COVID Vaccine Rollout

Radar On Market Access: Biden Probably Won't Roll Back New Prior Authorization Proposal

MMIT Reality Check on Breast Cancer HR+/HER2+ (Dec 2020)

Trends That Matter: Centene's ACA Expansion

Radar On Market Access: New-to-Market Oral Drugs May Not Always Have a Leg Up on Injectables

Radar On Market Access: First Round of Vaccines Are Expected to Be Free to the Public

MMIT Reality Check on Nonmetastatic Prostate Cancer (Dec 2020)

Perspectives on Biden Administration's Drug-Pricing Moves

Radar On Market Access: Employers Show Interest in Moving to ICHRAs

Radar On Market Access: Insurers Will Play Key Role in COVID Vaccine Distribution, Reimbursement

MMIT Reality Check on Ovarian Cancer (Dec 2020)

Trends That Matter for Growth Hormone Deficiency Treatments

Radar On Market Access: For PBMs, Amazon Pharmacy May Pose Only Indirect Threat

Radar On Market Access: MA Insurers Report Strong Performance, Predict Enrollment Growth

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo) (Nov 2020)

Perspectives on CMS Insulin Demo

Radar On Market Access: Teledermatology Program Reduces Patient Wait Time But Doesn't Increase Utilization

Radar On Market Access: Centene Expands ACA Footprint But Faces More Competition

MMIT Reality Check on Multiple Myeloma (Nov 2020)

Trends That Matter for Employer Health Benefits

Radar On Market Access: Insurer-Affiliated PBMs Propel Parent Firms' Revenues in Third Quarter

Radar On Market Access: Biden Administration's Drug-Pricing Moves May Be Limited

MMIT Reality Check on Cystic Fibrosis (Nov 2020)

Perspectives on MA Star Ratings

Radar On Market Access: What's Next for Health Insurers in a Likely Split Congress?

Radar On Market Access: Humana Reports Strong Earnings, But Expects Fourth-Quarter Loss

MMIT Reality Check on Chronic Lymphocytic Leukemia (Nov 2020)

Trends That Matter for Major PBMs' 2021 Formulary

Radar On Market Access: FDA's Approval of Sogroya May Change GH Class Management

Radar On Market Access: Centene Talks ACA's Future, Medicaid Rates in 3Q Earnings Call

MMIT Reality Check on Hepatocellular Carcinoma (Oct 2020)

Perspectives on the Future of ACA

Radar On Market Access: Employers Aim to Narrow Networks, Emphasize COEs, Expand Virtual Care Benefits

Radar On Market Access: Costlier PDPs, Cheaper MA-PDs Participate in CMS Insulin Demo

MMIT Reality Check on Psoriasis (Oct 2020)

Trends That Matter for CAR-T Therapies

Radar On Market Access: Racial Disparities Are Highlighted by Pandemic

Radar On Market Access: Average MA Star Ratings Fall Due to Increased Weights, Cut Points

MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2020)

Perspectives on Provider Consolidation

Radar On Market Access: Trump's $200 Medicare Drug Card Proposal Prompts Criticism

Radar On Market Access: CVS, OptumRx Exclude Brand-Name Inhalers From 2021 Formularies, Switch Up Diabetes Supplies

MMIT Reality Check on IBS-C (Oct 2020)

Trends That Matter on Trump Administration's Rebate Order

Radar On Market Access: COVID-19 Pandemic May Lower Health Care Costs, But Deferral Impact Exists

Radar On Market Access: If Preexisting Condition Protections Vanish, Health Insurers Probably Won't Cheer

MMIT Reality Check on Merkel Cell Carcinoma (Oct 2020)

Perspectives on Amazon-Sharp HealthCare Deal

Radar On Market Access: New Manufacturing Approach May Drive Down CAR-T Therapies' Prices

Radar On Market Access: Experts Remain Skeptical That SCOTUS Will Scuttle Entire ACA

MMIT Reality Check on Sickle Cell Disease (Sep 2020)

Trends That Matter for COVID Cost-Sharing Waivers

Radar On Market Access: Pandemic, Market Stability Encourage Major Insurers to Expand ACA Footprints

Radar On Market Access: As Payer M&A Slows Down, What's Next?

MMIT Reality Check on Schizophrenia (Sep 2020)

Perspectives on PBM Performance Amid COVID-19

Radar On Market Access: Prime Therapeutics Introduces Real Time Benefit Tool

Radar On Market Access: Trump's International Drug Pricing Order Is Still Missing; Rebate Order Draws Fire

MMIT Reality Check on Acute Migraine (Sep 2020)

Trends That Matter for Large Employers in 2021

Radar On Market Access: Amazon Moves Further Into Health Care Data, Sharp Deal Shows

Radar On Market Access: Some COVID Cost-Sharing Waivers Would Expire Soon

MMIT Reality Check on Breast Cancer HR+/HER2- (Sep 2020)

Perspectives on Telehealth Executive Order

Radar On Market Access: Insurers Expand Flu Vaccination Outreach to Blunt COVID-19 Effects

Radar On Market Access: USPS Delivery Slowdown Is Unlikely to Cause Major Rx Fill Disruption

MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (Aug 2020)

Trends That Matter for Prostate Cancer Treatments

Radar On Market Access: Payers Face Challenges to Enroll Newly Uninsured

Radar On Market Access: Large Employers Expect Cost Uncertainty, More Virtual Care in 2021

MMIT Reality Check on Ulcerative Colitis (Aug 2020)

Perspectives on UnitedHealth, Humana's Chronic Conditions Programs

Radar On Market Access: COVID-19 Pandemic Amps Up Interest in Home Care

Radar On Market Access: Anthem, Cigna, CVS Report Strong PBM Performance Amid COVID-19

MMIT Reality Check on Duchenne Muscular Dystrophy (Aug 2020)

Trends That Matter for Major Insurers' Performance Amid COVID-19

Radar On Market Access: Trump Administration Issues Telehealth Executive Order, More Acts Are Needed

Radar On Market Access: FDA Approved Two PARP Inhibitors for Prostate Cancer

MMIT Reality Check on Parkinson's Disease (Aug 2020)

Perspectives on Remdesivir's $3,120 Price Tag

Radar On Market Access: Anthem Warns of Greater Commercial Enrollment Drop in Second Half

Radar On Market Access: Experts Are Skeptical of Trump Administration's Drug Pricing Executive Orders

MMIT Reality Check on Kidney Cancer (July 2020)

Trends That Matter for Medicaid MCOs

Radar On Market Access: UnitedHealth, Humana Launch Programs for Chronic Conditions

Radar On Market Access: Manufacturers, Payers Wait on Federal COVID-19 Vaccine Distribution Plan

MMIT Reality Check on Bipolar Disorder (July 2020)

Perspectives on Trump Admin's COVID-19 Testing Payment Guidance

Radar On Market Access: Despite Coronavirus Surge, UnitedHealth Expects Care Utilization to Rebound This Year

Radar On Market Access: Trump Admin's COVID-19 Testing Payment Guidance Stirs Debate

MMIT Reality Check on Psoriatic Arthritis (July 2020)

Trends That Matter for Racial Disparities in MA Plans

Radar On Market Access: IngenioRx Acquires ZipDrug to Improve Medication Adherence, Affordability

Radar On Market Access: Remdesivir's $3,120 Price Tag Stirs Debate

MMIT Reality Check on Acute Lymphoblastic Leukemia (July 2020)

Perspectives on MedImpact’s New Program to Accelerate Pharmacogenomics

Radar On Market Access: Upheld Transparency Rule Is Slated to Reshape Payer-Provider Negotiations

Radar On Market Access: Reports Show Medicaid MCOs Are 'Dominant,' Increase Affordability

MMIT Reality Check on Hemophilia A or B With Inhibitors (July 2020)

Trends That Matter for DMD Therapies

Radar On Market Access: Insurers Are Required to Cover Only 'Medically Necessary' COVID-19 Tests

Radar On Market Access: CMS Proposes New Medicaid Best Price Rules for Pricey Therapies

MMIT Reality Check on Ankylosing Spondylitis (June 2020)

Perspectives on COVID-19 Vaccine Rollout

Radar On Market Access: Telehealth Regulation and Reimbursement Issue Sparks Debates

Radar On Market Access: CMS Report Shows Increasing Racial Disparities in MA Plans

MMIT Reality Check on Urothelial/Bladder Cancer (June 2020)

Trends That Matter: Enrollment Shift Into ACA Exchanges

Radar On Market Access: Pricey Treatments Face Challenges on Cost Sharing and Data Analysis

Radar On Market Access: MedImpact’s New Program Aims to Accelerate Pharmacogenomics

MMIT Reality Check on Endometriosis (June 2020)

Perspectives on ACA Exchanges Amid COVID-19

Radar On Market Access: Uncertainties Over Effectiveness and High Costs Surround DMD Therapies

Radar On Market Access: 2021 MA, Part D Bids Face Challenges Amid COVID-19

MMIT Reality Check on Chronic Idiopathic Constipation (June 2020)

Trends That Matter: The Future of Value-Based Agreements

Radar On Market Access: 1.7K Plans Apply for Trump Admin's Fixed-Insulin-Copay Program for Seniors

Radar On Market Access: Payers and PBMs May Play Key Role in COVID-19 Vaccine Rollout

MMIT Reality Check on Narcolepsy (May 2020)

Perspectives on Surge of Mental Health Meds Use Amid COVID-19

Radar On Market Access: Will COVID-19 Advance Automatic Health Insurance Enrollment?

Radar On Market Access: COVID-19 Pandemic May Change Rx Delivery Permanently

MMIT Reality Check on Low Testosterone (May 2020)

Trends That Matter for Medical-Benefit Drug Spending

Radar On Market Access: COVID-19 Pandemic Drives Home Infusion Utilization

Radar On Market Access: PBMs See Solid 1Q Results Despite Challenges Ahead

MMIT Reality Check on Pain Narcotic Opioid (May 2020)

Perspectives on Coronavirus Antibody Testing

Radar On Market Access: COVID-19 May Drive More Insurers Into ACA Exchanges

Radar On Market Access: CVS Sees COVID Testing Sites as Part of Bigger HealthHUB Strategy

MMIT Reality Check on Anemia — Chronic Kidney Disease (May 2020)

Trends That Matter for Biosimilar Medications Cost Savings

Radar On Market Access: Anthem, Cigna Brace for Recession-Induced Enrollment Shift

Radar On Market Access: Humana, Centene Maintain 2020 Earnings Outlook Amid COVID-19 Pandemic

MMIT Reality Check on Ophthalmic Anti-Inflammatory (Apr 2020)

Perspectives on ACA and Medicaid Enrollment Growth Amid COVID-19

Radar On Market Access: Oncology Drugs Drive Price Growth in Medical-Benefit Spend

Radar On Market Access: PBMs Say Use of Mental Health Meds Surges Amid COVID-19

MMIT Reality Check on Juvenile Idiopathic Arthritis (Apr 2020)

Trends That Matter for Bipolar Disorder Medications

Radar On Market Access: Medicaid MCOs Are Likely to See COVID-Related Enrollment Growth

Radar On Market Access: Insurers Are Now Required to Cover Coronavirus Antibody Testing

MMIT Reality Check on Acute Myeloid Leukemia (Apr 2020)

Perspectives on COVID-19 Outbreak's Impact on Drug Supply

Radar On Market Access: Slow Biosimilar Adoption and Opaque Markets Impede Potential Savings

Radar On Market Access: PBMs Use Dispensing Limits to Halt Hoarding of Trump-Touted Malaria Drugs

MMIT Reality Check on Opioid Dependence (Apr 2020)

Trends That Matter for Cost Impact of Coronavirus Treatment

Radar On Market Access: Amid COVID-19 Outbreak, CMS Relaxes Rules on MA Data Collection

MMIT Reality Check on COPD (Apr 2020)

Perspectives on New Generic HIV Drug

Radar On Market Access: Congress Could Pass Medicare Part D Reform Even Amid COVID-19 Outbreak

MMIT Reality Check on Glaucoma (Mar 2020)

Trends That Matter for Asthma Medications

Radar On Market Access: ACA Plans and Medicaid May See Enrollment Growth Amid COVID-19 Pandemic

Radar On Market Access: Questions Remain About Cost Impact of Coronavirus Treatment

MMIT Reality Check on Major Depressive Disorder (Mar 2020)

Perspectives on Legality of Closed Medicaid Formularies

Radar On Market Access: COVID-19 Outbreak Could Impact Drug Supply Long-Term

Radar On Market Access: Insurers, Pharma Spar Over Copay Accumulator Provision

MMIT Reality Check on Hereditary Angioedema (Mar 2020)

Trends That Matter for Diabetes Drug Costs

Radar On Market Access: Insurers Deploy Array of Strategies to Manage Asthma

Radar On Market Access: Florida Saw Strong MA, Individual Results and More Consolidations

MMIT Reality Check on HIV (Mar 2020)

Perspectives on ACA Exchange Draft Regulation

Radar On Market Access: New Generic HIV Drug May Impact PrEP Coverage, Not HIV Coverage

Radar On Market Access: Tenn. Blues’ White Bagging Policy Sees Pushback from Providers

MMIT Reality Check on Rheumatoid Arthritis (Feb 2020)

Trends That Matter for Nebraska Medicaid Expansion

Radar on Market Access: Future of Medicaid Work Requirements Dims After Arkansas Demo Is Struck Down Again

Radar On Market Access: CVS Touts Aetna’s Contribution; Molina Exchange Business Stumbles

MMIT Reality Check on Type 2 Diabetes (GLP-1 and Combo) (Feb 2020)

Perspectives on Part D Reform in 2020

Radar On Market Access: Payers Try New Strategies to Control Diabetes Drug Costs

Radar On Market Access: Some Experts Question Legality of Closed Medicaid Formularies

MMIT Reality Check on Neutropenia (Feb 2020)

Trends That Matter for Kansas Medicaid Expansion

Radar On Market Access: ACA Exchange Draft Regulation Drops

Radar On Market Access: New Oncology Biosimilar Launches Could Prompt Preferencing

MMIT Reality Check on Multiple Sclerosis (Feb 2020)

Perspectives on Consolidated PBMs in 2020

Radar On Market Access: Sanofi Backs Away From U.S. PCSK9 Market, While Novartis Bets Big With Inclisiran

Radar on Market Access: Nebraska Proposes A Two-Tiered Medicaid Expansion

MMIT Reality Check on Immune Globulin (PID) (Jan 2020)

Radar on Market Access: Disappointing MCOs, Supreme Court Won't Expedite Obamacare Decision

All posts

Learn more about MMIT's solutions

Posts by Topic

see all

Recent Posts

Subscribe to our blog

Payer Solutions

Pharma Solutions

Provider Solutions

Contact Us
info@mmitnetwork.com

© 2015 Managed Markets Insight & Technology, LLC
Privacy Policy